Affiliation:
1. From the Children's Hospital Boston, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA; New England Research Institutes, Watertown, MA; and Children's Hospital of Philadelphia, PA.
Abstract
Abstract
Treatment of patients with β-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized. We performed a cross-sectional study of 342 patients in the Registry of the National Institutes of Health-sponsored Thalassemia Clinical Research Network. Evidence of hepatitis C exposure was present in 35% of tested patients, was associated with age, and had a rate of spontaneous viral clearance of 33%. Ferritin levels ranged from 147 to 11 010 ng/mL (median, 1696 ng/mL). Median hepatic iron content was 7.8 mg/g dry weight and 23% of patients had values of 15 mg/g dry weight or higher. No patients 15 years or younger and 5% of patients aged 16 to 24 years had heart disease requiring medication. Ten percent had cirrhosis on biopsy. Endocrinologic complications were common among adults. Seventy-four (22%) patients had recent implantable central venous access devices (CVADs) placed. Among 80 episodes of bacteremia in 38 patients, 90% were attributable to the CVAD. Among 330 patients who had received deferoxamine chelation therapy, 224 (68%) reported no complications. We conclude that hepatitis C, iron-related organ dysfunction, and complications of iron chelation therapy are strongly age-dependent in North American patients with β-thalassemia.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference32 articles.
1. Nathan DG. Pioneers and modern ideas: prospective on thalassemia. Pediatrics. 1998;102: 281-283.
2. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341: 99-109.
3. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 1997;17: 407-421.
4. Old JM, Olivieri NF, Thein SL. Management and prognosis. In: Weatherall DJ, Clegg JB, eds. The Thalassaemia Syndromes. London: Blackwell Science; 2001: 630-685.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89: 739-761.
Cited by
357 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献